Shares of Bellerophon Therapeutics Inc. (BLPH) are soaring over 42% in pre-market today, after the company announced that expanded access treatment with the INOpulse inhaled nitric oxide system (iNO) was initiated for the first time in a patient with a diagnosis of the novel coronavirus disease (COVID-19) at the University of Miami School of Medicine.
from RTT - Before the Bell https://ift.tt/2UrDN1a
via IFTTT
No comments:
Post a Comment